Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

- Clinical benefit observed in over 60% of evaluable patients -

SEOUL, South Korea, Sept. 4 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported interim data from an ongoing phase 2 trial evaluating XL647 as first-line therapy for patients with non-small cell lung cancer (NSCLC). This open-label phase 2 trial is ongoing in previously untreated patients with stage IIIB or IV NSCLC who have adenocarcinoma histology and meet one of the following three criteria: Asian descent, female gender, or no or minimal smoking history. XL647 is administered orally, at a dose of 350 mg on Days 1-5 of repeated 14-day cycles.

To date, over 60% of evaluable patients in the phase 2 study have had partial responses (PR) or stable disease (SD) as their best response. Importantly, responses have been observed in patients with and without activating mutations in the epidermal growth factor receptor (EGFR), a target of XL647. Activating mutations in EGFR have been associated with improved sensitivity to other EGFR inhibitors. Dr. Shirish Gadgeel of Karmanos Cancer Institute at Wayne State University presented the data today in a poster (Abstract P3-136) at the 12th International Association for the Study of Lung Cancer World Conference on Lung Cancer, which is being held in Seoul, South Korea.

Key data points reported by Investigators:

-- XL647 has demonstrated anti-tumor activity in patients with previously

untreated NSCLC: >60% of evaluable patients experienced clinical

benefit as their best response (8 PR and 11 SD out of 30 evaluable

patients).

-- Of the 8 patients who experienced partial responses, 4 had EGFR exon 19

deletions, 1 had an EGFR L858R mu
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Verenium Corporation (Nasdaq: VRNM ), ... and commercialization of high-performance enzymes, today announced that ... present at two upcoming conferences. (Logo: ... the Second Annual Marcum LLP Microcap Conference on Thursday, ... New York City.  The presentation is scheduled to begin ...
(Date:5/23/2013)... South Korea , May 23, 2013 /PRNewswire/ ... with SillaJen, Inc., a private biotherapeutics and contract ... targeted biological products for cancer, announced today a ... in patients treated with the oncolytic and immunotherapeutic ... This research was published in the May ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 ... ancestry tracing for people of African descent, today ... product offering. For people of all races, myDNAmix ... from five distinct populations: Indigenous Americas (Native American), ... India Subcontinent. , Originally launched in ...
(Date:5/23/2013)... Bed bugs compromised Penn State. ... confirmed it. Meanwhile, My Cleaning Products offered complimentary samples of ... the pests without using harmful chemical elements. , Based ... the affected building was actually a dormitory , My ... made on May 13 and bed bug presence was confirmed ...
Breaking Biology Technology:Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... Emphasis on Drug Development and Recent ... Private Equity ... (Nasdaq: LXRX ) announced several changes to the,composition of ... and the completion of a major strategic financing,with Invus, LP. ...
... Sept. 25 NanoBio(R) Corporation, a,biopharmaceutical company developing ... prevent serious infections, today announced,the addition of four ... Lyou-fu Ma, PharmD, Ph.D.; Susan Ciotti, Ph.D.; Robert ... NanoBio in developing and commercializing,its novel topical anti-infectives ...
... SeqWright, Inc., an international,leader in the field ... Applied Biosystems (ABI) to purchase ABI,s next generation,SOLiD(TM) ... to offer commercial access to the latest in ... between,SeqWright and ABI that grows stronger with time. ...
Cached Biology Technology:Lexicon Appoints Judith Swain, M.D. to Board of Directors 2Lexicon Appoints Judith Swain, M.D. to Board of Directors 3Lexicon Appoints Judith Swain, M.D. to Board of Directors 4NanoBio Expands Drug Development Team for Its Anti-Infective Products 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 3SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System 2
(Date:5/23/2013)... HOUSTON (May 23, 2013) A new report ... responsible for helping pupils engage in at least 60 ... school day. , No more than half of American ... hour of vigorous or moderate intensity physical activity daily, ... , "Because children are in school for nearly half ...
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... 160 participants gathered this week for the seventh ... year,s topic, "Synthetic Biology," brought together scientists, engineers, ... and social issues surrounding the emerging field of ... molecular biology at Princeton University and this year,s ...
... 2009 -- A USDOE and USDA study concluded that ... cropland pasture could be converted from current uses to ... which biomass could be harvested for use as a ... monoculture from which substantial quantities of biomass are removed ...
... string of recent discoveries about the multiple health benefits of ... awareness of the huge numbers of people who are deficient ... of it as "nature,s antibiotic." On issues ranging from ... disease and even vulnerability to influenza, vitamin D is now ...
Cached Biology News:Synthetic biology offers new opportunities for interdisciplinary collaboration 2Switchgrass produces biomass efficiently 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
... PGE1-d4 contains 4 deuterium atoms at the ... is intended for use as an internal ... GC- or LC-mass spectrometry. PGE1 is the ... but it is virtually undetectable in the ...
Biology Products: